Security key
75629V104
RECURSION PHARMACEUTICALS, INC. - COMMON STOCK (RXRX)
CUSIP: 75629V104
Q4 2024 13F Holders as of 31 Dec 2024
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 304,544,141
- Total 13F value
- $2,058,776,356
- Share change
- +39,617,419
- Put/Call ratio
- 129%
- SEC-reported price per share
- $6.76
- Number of holders
- 310
- Value change
- +$268,240,445
- Number of buys
- 177
- Number of sells
- 93
- Shares outstanding
- 525,850,455
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2024
Institutions
310
Top holders
10
RXRX full security history
Ownership snapshot
Full 13F holder table
RECURSION PHARMACEUTICALS, INC. SEC filings
RECURSION PHARMACEUTICALS, INC. company facts
Broader feeds
Ownership snapshot
Top reported holders of RXRX - RECURSION PHARMACEUTICALS, INC. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BAILLIE GIFFORD & CO
Disclosed value leader
ARK Investment Management...
Comparable rows
2/15
Latest evidence
30 Sep 2024
13F
13D/G
3/4/5
Lead comparable stake: 6.5%
13 rows are not safely comparable across share classes.
13D/G row: BAILLIE GIFFORD & CO
Showing 1-6 of 15 holder rows.
Quick read
BAILLIE GIFFORD & CO leads the comparable SEC ownership view at 6.5%.
2 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BAILLIE GIFFORD & CO's linked filing trail.
Comparable ownership
Top 2
BAILLIE GIFFORD & CO
6.5%
RA CAPITAL MANAGEMENT, L.P.
2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BAILLIE GIFFORD & CO |
13F
13D/G
Company
|
6.5%
Reported 13D/G
· 31 Dec 2024
|
$166,330,743
25,239,870 shares
|
— | 30 Sep 2024 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
Company
|
2%
Reported 13D/G
· 31 Dec 2024
|
$101,384,613
15,384,615 shares
|
— | 30 Sep 2024 |
| Lux Ventures IV, L.P. |
3/4/5
Former 10% Owner
|
—
denominator unverified
|
$137,710,376
13,021,519 shares
|
— | 07 Dec 2021 |
| Mubadala Investment Co PJSC |
3/4/5
13F
10%+ Owner · Company
|
—
denominator unverified
|
$137,333,970
12,985,927 shares
|
— | 02 Mar 2023 |
| Zachary Bogue |
3/4/5
Director, 10%+ Owner
|
—
denominator unverified
|
$39,514,048
3,736,341 shares
|
— | 03 Jul 2023 |
| MIC Capital Partners (Public) Parallel Cayman, LP |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$14,688,335
1,388,889 shares
|
— | 01 Nov 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
310
Shares
304,544,141
Rows available
310
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
262
Q4 2024 holders
310
Holder diff
48
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 value | Q4 2024 value | Value change | Value Chg % |
|---|